MSN Pharmaceuticals, Inc. v. Novartis Pharmaceuticals Corp.

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent

Question(s) Presented

“In a patent case, ‘after-arising technology’ is technology that was not invented until after the patent’s filing. Neither this Court nor the Federal Circuit en banc has addressed the disclosure rules for after-arising technology. One line of Federal Circuit case law holds that when a patentee secures a claim construction that ensnares, as infringing, an accused device that features after-arising technology, the patentee risks invalidating its own patent under 35 U.S.C. § 112(a), which requires a patentee to describe and teach the claimed invention. A contradictory line of Federal Circuit decisions, including the decision below, carves out an exception for after-arising technology. This line holds that ‘later-existing state of the art . . . may not be properly considered’ in the validity analysis. After-arising technology, that is, may not ‘reach back and invalidate’ a patent. Yet that proposition conflicts with The Incandescent Lamp Patent, 159 U.S. 465 (1895). Edison’s after-arising bamboo-filament technology exposed the invalidity of Sawyer and Man’s patent for an electric lightbulb.”

The question presented is: Whether, in a patent-infringement suit, a court may consider after-arising technology to hold that the patent is invalid under § 112(a) of the Patent Act.”

Posts About this Case

Date
Proceedings and Orders
June 11, 2025
Application (24A1215) granted by The Chief Justice extending the time to file until August 22, 2025.
September 3, 2025
DISTRIBUTED for Conference of 9/29/2025.
September 8, 2025
Response Requested. (Due October 8, 2025)
September 18, 2025
Motion to extend the time to file a response is granted and the time is extended to and including November 7, 2025.
November 25, 2025
DISTRIBUTED for Conference of 12/12/2025.
December 15, 2025
Petition DENIED.